Mersana Therapeutics has entered into an option agreement with GSK for the codevelopment and commercialization of XMT-2056, an Immunosynthen antibody-drug conjugate (ADC) that targets a novel epitope of HER2.

The FDA has cleared an IND application for Gan & Lee Pharmaceuticals' GZR-4 allowing initiation of a phase I trial in the U.S.

A radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI) has shown that intravenous administration of Athersys' MultiStem (invimestrocel) provided benefit in an animal model of acute radiation syndrome (ARS).

BeiGene has discovered GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Anticancer Bioscience and the J Michael Bishop Institute of Cancer Research have described fused azepine compounds reported to be useful for the treatment of cancer.

The National Institute of Pharmaceutical R&D (Beijing) has identified condensed heterocyclic compounds acting as insulin secretagogues and gluconeogenesis inhibitors reported to be useful for the treatment of diabetes.

Shenzhen Chipscreen Biosciences and Chengdu Chipscreen Pharmaceutical have presented new ATR kinase inhibitors reported to be useful for the treatment of cancer.

Shanghai Shengdi Pharmaceutical, Shanghai Senhui Pharmaceutical and Jiangsu Hengrun Pharmaceutical have divulged new cephems (cephalosporins) reported to be useful for the treatment of Gram-negative bacterial infections.

With the aim of assessing the implication of gap junction protein connexin 43 (Cx43) in angiogenesis, human pulmonary microvascular endothelial cells were transfected with Cx43-targeting siRNA or Cx43-overexpressing recombinant plasmid vector.

Researchers aimed to evaluate the consequence of CD47 inhibition on lung tumor growth in syngeneic models.